Familial risk for lung cancer (Review)
- Authors:
- Madiha Kanwal
- Xiao‑Ji Ding
- Yi Cao
-
Affiliations: Laboratory of Molecular and Experimental Pathology, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650223, P.R. China - Published online on: December 20, 2016 https://doi.org/10.3892/ol.2016.5518
- Pages: 535-542
This article is mentioned in:
Abstract
|
Brentnall T: Management strategies for patients with hereditary pancreatic cancer. Curr Treat Options Oncol. 6:437–445. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Riaz SP, Linklater KM, Page R, Peake MD, Møller H and Lüchtenborg M: Recent trends in resection rates among non-small cell lung cancer patients in England. Thorax. 67:811–814. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Chambers A, Routledge T, Pilling J and Scarci M: In elderly patients with lung cancer is resection justified in terms of morbidity, mortality and residual quality of life? Interact Cardiovasc Thorac Surg. 10:1015–1021. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Cao Y and Gao HP: Prevalence and causes of air pollution and lung cancer in Xuanwei city and Fuyuan County, Yunnan province, China. Front Med. 6:217–220. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
World Health Organization, . Cancer. Fact Sheet No 297. http://www.who.int/mediacentre/factsheets/fs297/en/Accessed March 20, 2015. | |
|
Lichtenstein P, Holm NV, Verksalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A and Hemminki K: Environmental and heritable factors in the causation of cancer-analyses of cohort of twins from Sweden, Denmark, and Finland. N Engl J Med. 343:78–85. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
American Cancer Society, . Cancer Facts & Figures 1993. http://www.cancer.org/research/cancerfactsstatistics/allcancerfactsfigures/Accessed March 20, 2015. | |
|
Geneste O, Camus AM, Castegnaro M, Petruzzelli S, Macchiarini P, Angeletti CA, Giuntini C and Bartsch H: Comparison of pulmonary DNA adduct levels, measured by 32P-postlabelling and aryl hydrocarbon hydroxylase activity in lung parenchyma of smokers and ex-smokers. Carcinogenesis. 12:1301–1305. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
Smith KR, Samet JM, Romieu I and Bruce N: Indoor air pollution in developing countries and acute lower respiratory infection in children. Thorax. 55:518–532. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Raaschou-Nielsen OR, Andersen ZJ, Hvidberg M, Jensen SS, Ketzel M, Sørensen M, Loft S, Overvad K and Tjønneland A: Lung cancer incidence and long-term exposure to air pollution from traffic. Environ Health Perspect. 119:860–865. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Mu L, Liu L, Niu R, Zhao B, Shi J, Li Y, Swanson M, Scheider W, Su J, Chang SC, et al: Indoor air pollution and risk of lung cancer among chinese female non-smokers. Cancer Causes Control. 24:439–450. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Barone-Adesi F, Chapman RS, Silverman DT, He X, Hu W, Vermeulen R, Ning B, Fraumeni JF Jr, Rothman N and Lan Q: Risk of lung cancer associated with domestic use of coal in Xuanwei, China: Retrospective cohort study. BMJ. 345:e54142012. View Article : Google Scholar : PubMed/NCBI | |
|
International Agency for Research on Cancer, . IARC monographs on the evaluation of carinogenic risks to humans. 2011.http://monographs.iarc.fr/ENG/Classification/Accessed March 20, 2015. | |
|
Ohyama K, Ito T and Kanisawa M: The roles of diesel exhaust-particle extracts and the promotive effects of NO2 and/or SO2 exposure on rat lung tumorigenesis. Cancer. 139:189–197. 1999. | |
|
Lee WJ, Teschke K, Kauppinen T, Andersen A, Jäppinen P, Szadkowska-Stanczyk I, Pearce N, Persson B, Bergeret A, Facchini LA, et al: Mortality from lung cancer in workers exposed to sulfur dioxide in the pulp and paper industry. Environ Health Perspect. 110:991–995. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Langseth H and Andersen A: Cancer incidence among male pulp and paper workers in Norway. Scand J Work Environ Health. 26:99–105. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Pope CA III, Burnett RT, Thun MJ, Calle EE, Krewski D, Ito K and Thurston GD: Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution. JAMA. 287:1132–1141. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Braun MM, Caporaso NE, Page WF and Hoover RN: Genetic component of lung cancer: Cohort study of twins. Lancet. 344:440–443. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Neale MC and Cardon LR: Methodology for genetic studies of twin and families. 1st. Kluwer Academic Publishers; Dordrecht: pp. 237–238. 1992 | |
|
Ahlbom A, Lichtenstein P, Malmström H, Feychting M, Hemminki K and Pedersen NL: Cancer in twins: Genetic and non-genetic familial risk factor. J Nat Canc Isnt. 89:287–293. 1997. View Article : Google Scholar | |
|
Carmelli D, Swan GE, Robinette D and Fabsitz R: Genetic influence on smoking - a study of male twins. N Engl J Med. 327:829–833. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Coté ML, Liu M, Bonassi S, Neri M, Schwartz AG, Christiani DC, Spitz MR, Muscat JE, Rennert G, Aben KK, et al: Increased risk of lung cancer in individuals with a family history of the disease: A pooled analysis from the International lung cancer consortium. Eur J Cancer. 48:1957–1968. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Bailey-Wilson JE, Amos CI, Pinney SM, Petersen GM, de Andrade M, Wiest JS, Fain P, Schwartz AG, You M, Franklin W, et al: A major lung cancer susceptibility locus maps to chromosome 6q23-25. Am J Hum Genet. 75:460–474. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Mitsuuchi Y and Testa JR: Cytogenetics and molecular genetics of lung cancer. Am J Med Genet. 115:183–188. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Zochbauer-Muller ZS, Gazdar AF and Minna JD: Molecular pathogenesis of lung cancer. Annu Rev Physiol. 64:681–708. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Schenk T, Ackermann J, Brunner C, Schenk P, Zojer N, Roka S and Drach J: Detection of chromosomal aneuploidy by interphase fluorescence in situ hybridization in bronchoscopically gained cells from lung cancer patients. Chest. 111:1691–1696. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Kang JU, Koo SH, Kwon KC, Park JW, Shin SY, Kim JM and Jung SS: High frequency of genetic alterations in non-small cell lung cancer detected by multi-target fluorescence in situ hybridization. J Korean Med Sci. 22(Suppl): S47–S51. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Kettunen E, Salmenkivi K, Vuopala K, Toljamo T, Kuosma E, Norppa H, Knuutila S, Kaleva S, Huuskonen MS and Anttila S: Copy number gains on 5p15, 6p11-q11, 7p12, and 8q24 are rare in sputum cells of individuals at high risk of lung cancer. Lung Cancer. 54:169–176. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Luk C, Tsao MS, Bayani J, Shepherd F and Squire JA: Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization. Cancer Genet Cytogenet. 125:87–99. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Lu YJ, Dong XY, Shipley J, Zhang RG and Cheng SJ: Chromosome 3 imbalances are the most frequent aberration found in non-small cell lung carcinoma. Lung Cancer. 23:61–66. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Testa JR, Siegfried JM, Liu Z, Hunt JD, Feder MM, Litwin S, Zhou JY, Taguchi T and Keller SM: Cytogenetic analysis of 63 non-small cell lung carcinomas: Recurrent chromosome alterations amid frequent and widespread genomic upheaval. Gene Chrom Cancer. 11:178–194. 1994. View Article : Google Scholar | |
|
Toyooka S, Suzuki M, Tsuda T, Toyooka KO, Maruyama R, Tsukuda K, Fukuyama Y, Iizasa T, Fujisawa T, Shimizu N, et al: Dose effect of smoking on aberrant methylation in non-small cell lung cancer. Int J Cancer. 110:462–464. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Wistuba II, Berry J, Behrens C, Maitra A, Shivapurkar N, Milchgrub S, Mackay B, Minna JD and Gazdar AF: Molecular changes in the bronchial epithelium of patients with small cell lung cancer. Clin Cancer Res. 6:2604–2610. 2000.PubMed/NCBI | |
|
Sato S, Nakamura Y and Tsuchiya E: Difference of allelotype between squamous cell carcinoma and adenocarcinoma of the lung. Cancer Res. 54:5652–5655. 1994.PubMed/NCBI | |
|
Osada H and Takahashi T: Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer. Oncogene. 21:7421–7434. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Downward J: The RAS superfamily of small GTP binding proteins. Trends Biochem Sci. 15:469–472. 1990. View Article : Google Scholar : PubMed/NCBI | |
|
Riely GJ, Kris MG, Rosenbaum D, Marks J, Li A, Chitale DA, Nafa K, Riedel ER, Hsu M, Pao W, et al: Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res. 14:5731–5734. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Rodenhuis S and Slebos RJ: Clinical significance of Ras oncogene activation in human lung cancer. Cancer Res. 52:(Suppl 9). S2665–S2669. 1992. | |
|
Bethune G, Bethune D, Ridgway N and Xu Z: Epidermal growth factor receptor (EGFR) in lung cancer: An overview and update. J Thorac Dis. 2:48–51. 2010.PubMed/NCBI | |
|
Inamura K, Ninomiya H, Ishikawa Y and Matsubara O: Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features? Arch Pathol Lab Med. 134:66–72. 2010.PubMed/NCBI | |
|
Zhou CC, Zhou SW, Pan H, Su B and Gao ZQ: Detection of epidermal growth factor receptor mutations in non-small cell lung cancer by real-time PCR using TaqMan-MGB probes. Zhonghua Zhong Liu Za Zhi. 29:119–123. 2007.(In Chinese). PubMed/NCBI | |
|
Gupta R, Dastane AM, Forozan F, RileyPortuguez A, Chung F, Lopategui J and Marchevsky AM: Evaluation of EGFR abnormalities in patients with pulmonary adenocarcinoma: The need to test neoplasms with more than one method. Mod Pathol. 22:128–133. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Ladanyi M and Pao W: Lung adenocarcinoma: Guiding EGFR-targeted therapy and beyond. Mod Pathol. 21:(Suppl 2). S16–S22. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Sun S, Schiller JH and Gazdar AF: Lung cancer in never smokers-a different disease. Nat Rev Cancer. 7:778–790. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Lin L, Asthana S, Chan E, Bandyopadhyay S, Martins MM, Olivas V, Yan JJ, Pham L, Wang MM, Bollag G, et al: Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proc Natl Acad Sci USA. 111:E748–E757. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Tissot C, Couraud S, Tanguy R, Bringuier PP, Girard N and Souquet PJ: Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations. Lung Cancer. 91:23–28. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Garnett MJ and Marais R: Guilty as charged: B-RAF is a human oncogene. Cancer Cell. 6:313–319. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Mar N, Vredenburgh JJ and Wasser JS: Targeting HER2 in the treatment of non-small cell lung cancer. Lung Cancer. 87:220–225. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Shimamura T, Ji H, Minami Y, Thomas RK, Lowell AM, Shah K, Greulich H, Glatt KA, Meyerson M, Shapiro GI and Wong KK: Non-small cell lung cancer and Ba/F3 transformed cell harboring the ERBB2 G776ins V_G/C mutations are sensitive to the dual specific epidermal growth factor receptor and ERBB inhibitor HKI-272. Cancer Res. 66:6487–6491. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Yamamoto H, Higasa K, Sakaguchi M, Shien K, Soh J, Ichimura K, Furukawa M, Hashida S, Tsukuda K, Takigawa N, et al: Novel germline mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas. J Natl Can Inst. 106:djt3382014. View Article : Google Scholar | |
|
Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, et al: Identification of transforming EML4-ALK fusion gene non-small cell lung cancer. Nature. 448:561–566. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, et al: Anaplastic lymphoma kinase inhibition in non-small cell lung cancer. N Engl J Med. 363:1693–1703. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Sasaki T, Rodig SJ, Chirieac LR and Jänne PA: The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Can. 46:1773–1780. 2010. View Article : Google Scholar | |
|
Cai W, Li X, Su C, Fan L, Zheng L, Fei K, Zhou C, Manegold C and Bindert GC: ROS1 fusions in Chinese patients with non-small-cell lung cancer. Ann Oncol. 24:1822–1827. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H, et al: RET, ROS1 and ALK fusions in lung cancer. Nat Med. 18:378–381. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, SiwakTapp S, Gonzalez A, Fang R, et al: ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 30:863–870. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T, Sakamoto H, Tsuta K, Furuta K, Shimada Y, et al: KIF5B-RET fusion in lung adenocarcinoma. Nat Med. 18:375–377. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wang R, Hu H, Pan Y, Li Y, Ye T, Li C, Lou X, Wang L, Li H, Zhang Y, et al: RET fusions define a unique molecular and clinic pathologic subtype of non-small-cell lung cancer. J Clin Oncol. 30:4352–4359. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Eng C: RET proto-oncogene in the development of human cancer. J Clin Oncol. 17:380–393. 1999.PubMed/NCBI | |
|
Chao BH, Briesewitz R and Villalona-Calero MA: RET fusion genes in non-small-cell lung cancer. J Clin Oncol. 30:4439–4441. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Bodner SM, Minna JD, Jensen SM, D'Amico D, Carbone D, Mitsudomi T, Fedorok J, Buchhagen DL, Nau MM and Gazdar AF: Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene. 7:743–749. 1992.PubMed/NCBI | |
|
Husgafvel-Pursiainen KH, Boffetta P, Kannio P, Nyberg F, Pershagen G, Mukeria A, Constantinescu V, Fortes C and Benhmou S: P53 Mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer. Cancer Res. 60:2906–2911. 2000.PubMed/NCBI | |
|
Tammemagi MC, McLaughlin JR and Bull SB: Meta-analyses of p53 tumor suppressor gene alterations and clinicopathological features in resected lung cancers. Cancer Epidemiol Biomark Prev. 8:625–634. 1999. | |
|
Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et al: Unique microRNA profiles in lung cancer diagnosis and prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D and Slack FJ: RAS is regulated by the let-7 microRNA family. Cell. 120:635–647. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Lee YS and Dutta A: The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev. 21:1025–1030. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Weiss GJ, Bemis LT, Nakajima E, Sugita M, Birks DK, Robinson WA, VarellaGarcia M, Bunn PA Jr, Haney J, Helfrich BA, et al: EGFR regulation by microRNA in lung cancer: Correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann Oncol. 19:1053–1059. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
He L, He X, Lim LP, Stanchina ED, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, et al: A microRNA component of the p53 tumor suppressor network. Nature. 447:1130–1134. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylkäs K, Roberts J, Lee A, Subramanian D, De Leeneer K, Fostira F, et al: Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 371:497–506. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Thompson ER, Rowley SM, Sawyer S, kConFab, Eccles DM, Trainer AH, Mitchell G, James PA and Campbell IG: Analysis of RAD51D in ovarian cancer patients and families with a history of ovarian or breast cancer. PloS One. 8:e547722013. View Article : Google Scholar : PubMed/NCBI | |
|
Imyanitov EN and Moiseyenko VM: Drug therapy for hereditary cancers. Hered Cancer Clin Pract. 9:52011. View Article : Google Scholar : PubMed/NCBI | |
|
Li X and Hemminki K: Inherited predisposition to early onset lung cancer according to histological type. Int J Cancer. 112:451–457. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Lindor NM, McMaster ML, Lindor CJ and Greene MH: National Cancer Institute, Division of Cancer Prevention, Community Oncology and Prevention Trials Research Group: Concise handbook of familial cancer susceptibility syndromes-second edition. J Natl Cancer Inst Monogr. 38:1–93. 2008. | |
|
Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J and Schlumberger M: Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 28:767–772. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Imyanitov EN and Byrski T: Systemic treatment for hereditary cancer: A 2012 update. Can Clin Pract. 11:22013. | |
|
Narod SA: BRCA mutations in the management of breast cancer: The state of the art. Nat Rev Clin Oncol. 7:702–707. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Joosse SA, Brandwijk KI, Mulder L, Wesseling J, Hannemann J and Nederlof PM: Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors. Genes Chromosomes Cancer. 50:71–81. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Half E, Bercovich D and Rozen P: Familial adenomatous polyposis. Orphanet J Rare Dis. 4:222009. View Article : Google Scholar : PubMed/NCBI | |
|
Kennelly RP, Gryfe R and Winter DC: Familial colorectal cancer: Patient assessment, surveillance and surgical management. Eur J Surg Oncol. Jul 27–2016.(Epub ahead of print). View Article : Google Scholar | |
|
Vilar E and Gruber SB: Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol. 7:153–162. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Gaughan EM, Cryer SK, Yeap BY, Jackman DM and Costa DB: Family history of lung cancer in never smokers with non-small cell lung cancer and its association with tumor harboring EGFR mutations. Lung Cancer. 79:193–197. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Liu P, Vikis HG, Wang D, Lu Y, Wang Y, Schwartz AG, Pinney SM, Yang P, de Andrade M, Petersen GM, et al: Familial aggregation of common sequence variants on 15q24-25.1 in lung cancer. J Natl Cancer Inst. 100:1326–1330. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Wu AH, Fontham ET, Reynolds P, Greenberg RS, Buffler P, Liff J, Boyd P and Correa P: Family history of cancer and risk of lung cancer among lifetime non-smoking women in the United States. Am J Epidemiol. 143:535–542. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Bromen K, Pohlabeln H, Jahn I, Ahrens W and Jöckel KH: Aggregation of lung cancer in families: Results from a population based case control study in Germany. Am J Epidemiol. 152:497–505. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Hemminki K, Dong C and Vaittinen P: Cancer risks to spouses and offspring in the family-cancer database. Genet Epidemiol. 20:247–257. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Hemminki K and Li X: Familial risk for lung cancer by histology and age of onset: Evidence for recessive inheritance. Exp Lung Res. 31:205–215. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Jonsson S, Thorsteinsdottir U, Gudbjartsson DF, Jonsson HH, Kristleifur K, Arnason S, Gudnason V, Isaksson HJ, Hallgrimsson J, Gulcher JR, et al: Familial risk of lung carcinoma in the icelandic population. JAMA. 292:2977–2983. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Jin T, Zhou X and He X: The general measurement of genetic factors on lung cancer in Xuanwei, China. Zhongguo Fei Ai Za Zhi. 4:354–356. 2001.(In Chinese). PubMed/NCBI | |
|
Jin Y, Xu Y, Xu M and Xue S: Increased risk of cancer among relatives of patients with lung cancer in China. BMC Cancer. 5:1462005. View Article : Google Scholar : PubMed/NCBI | |
|
Socialstyrelsen, . Cancer Incidence in Sweden 2000. http://www.socialstyrelsen.se/publikationer2002/2002-42-5Accessed March 20, 2015. | |
|
Nitadori J, Inoue M, Iwasaki M, Otani T, Sasazuki S, Nagai K and Tsugane S: Association between lung cancer incidence and family history of lung cancer: Data from a large-scale population-based cohort study, the JPHC study. Chest. 130:968–975. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Coté ML, Kardia SL, Wenzlaff AS, Ruckdeschel JC and Schwartz AG: Risk of lung cancer among white and black relatives of individuals with early-onset lung cancer. JAMA. 293:3036–3042. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Osann KE: Lung cancer in women: The importance of smoking, family history of cancer and medical history of respiratory diseases. Cancer Res. 51:4893–4897. 1991.PubMed/NCBI | |
|
Yu XJ, Yang MJ, Zhou B, Wang GZ, Huang YC, Wu LC, Cheng X, Wen ZS, Huang JY, Zhang YD, et al: Characterization of somatic mutations in air pollution-related lung cancer. EBioMedicine. 2:583–590. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Spitz MR, Amos CI, Dong Q, Lin J and Wu X: The CHRNA5-A3 region on chromosome 15q24-25.1 is a risk factor both for nicotine dependence and for lung cancer. J Natl Cancer Inst. 100:1552–1556. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, Zaridze D, Mukeria A, SzeszeniaDabrowska N, Lissowska J, Rudnai P, et al: A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature. 452:633–637. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
You M, Wang D, Liu P, Vikis H, James M, Lu Y, Wang Y, Wang M, Chen Q, Jia D, et al: Fine mapping of chromosome 6q23-25 region in familial lung cancer families reveals RGS17 as a likely candidate gene. Clin Cancer Res. 15:2666–2674. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Bell DW, Gore I, Okimoto RA, GodinHeymann N, Sordella R, Mulloy R, Sharma SV, Brannigan BW, Mohapatra G, Settleman J and Haber DA: Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet. 37:1315–1316. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Oxnard GR, Miller VA, Robson ME, Azzoli CG, Pao W, Ladanyi M and Arcila ME: Screening for germline EGFR T790M mutations through lung cancer genotyping. J Thorac Oncol. 7:1049–1052. 2012. View Article : Google Scholar : PubMed/NCBI |
